Vinblastine (Vinca Indole Alkaloid · Antimitotic · Informational)

Compound	Vinblastine (Vincaleukoblastine; VLB; Velban)
Chemical class	Alkaloid — Indole (dimeric Vinca alkaloid; catharanthine-vindoline scaffold)
CAS	865-21-4
Primary source	Catharanthus roseus (Madagascar periwinkle), aerial parts
Key applications	Pharmaceutical antineoplastic (Hodgkin lymphoma, testicular cancer); microtubule inhibitor; informational-only
Claim strength	High (pharmaceutical)
Typical form	Pharmaceutical injectable (vinblastine sulfate); not a supplement ingredient
Buy from Herbuno	Informational reference — see HerbIQ Compound Index →

Name origin: Vinblastine — originally vincaleukoblastine, a name recording its discovery through the leukocyte-depleting activity of periwinkle extracts — is a dimeric vinca alkaloid from Catharanthus roseus. Like vincristine it couples a catharanthine unit to a vindoline ring, and the two compounds differ only by a single N-substituent on the vindoline portion. It was the first of the periwinkle vinca alkaloids to be isolated and structurally characterised, and it opened the therapeutic story of the whole class. Traditional use: The compound emerged, as vincristine did, from mid-twentieth-century investigation of Madagascar periwinkle's folk reputation as an antidiabetic plant. Researchers pursuing a hypoglycaemic agent instead observed marked myelosuppression in animals, and that toxic effect — not the hoped-for glucose lowering — became the basis of a new class of anticancer drugs. Research trajectory: Vinblastine became a mainstay of curative regimens for Hodgkin lymphoma (notably the ABVD combination) and for testicular germ-cell tumours. Comparative biophysical studies of its interaction with tubulin, set alongside vincristine and vinorelbine, have mapped both the shared self-association behaviour of the class and the subtle affinity differences among its members Lobert 1996. Safety context: Vinblastine is a prescription cytotoxic drug whose principal dose-limiting toxicity is bone-marrow suppression rather than the neuropathy that limits vincristine. It has no dietary-supplement application and is included here strictly as a formulator and researcher reference to the vinca family.

---

Evidence for Vinblastine Applications

Antimitotic mechanism: Vinblastine binds tubulin and inhibits microtubule assembly, and it induces tubulin to self-associate into coiled spiral aggregates, arresting dividing cells in mitosis. Comparative sedimentation and binding studies place its tubulin affinity and self-association behaviour alongside vincristine and vinorelbine, showing that all three share a ligand-mediated self-association mechanism while differing quantitatively Lobert 1996. This microtubule-directed action underlies its antineoplastic effect. Claim strength: High (pharmaceutical context).

Clinical oncology use: Vinblastine is a component of curative combination chemotherapy for Hodgkin lymphoma and testicular cancer, dosed intravenously under oncological supervision with careful attention to blood counts. Its distinct, non-overlapping toxicity relative to alkylating agents and platinum compounds is precisely why it fits well into multi-drug regimens where cumulative marrow toxicity must be balanced across agents. Claim strength: High (pharmaceutical context).

Myelosuppression profile: Where vincristine's cumulative toxicity is neurological, vinblastine's is haematological: neutropenia is the characteristic and dose-limiting effect. This single-substituent-driven divergence in toxicity is one of the clearest structure-activity lessons in the vinca class and directly shapes which agent is chosen for a given regimen. Claim strength: High (pharmaceutical context).

Biosynthetic and production interest: Vinblastine's very low natural abundance and structurally complex dimeric architecture make it a leading target for metabolic engineering and total or semi-synthesis. The intact dimer is present at trace levels, so its supply depends on precursor extraction and coupling, and researchers have reconstituted long segments of the pathway in engineered hosts to secure alternative supply. Claim strength: Moderate.

Relationship to the wider class: Vinblastine is the parent structure from which several semisynthetic analogues (including vinorelbine and vindesine) were developed, each tuned for a different affinity or toxicity balance, making it a reference point for the entire vinca-alkaloid drug family. Claim strength: Moderate.

---

Dosage & Formulator Specification

Vinblastine is a pharmaceutical cytotoxic agent with no supplement application and no consumer dosing. It is administered as a sterile intravenous injection of vinblastine sulfate by oncology professionals at milligram-per-square-metre doses, with treatment guided by haematological monitoring because neutropenia is the expected dose-limiting effect.

No botanical preparation standardised to vinblastine is appropriate for supplement use, and the reason is categorical rather than technical: it is a controlled antineoplastic drug. Catharanthus roseus herb is not a food-safe supplement botanical owing to its cytotoxic alkaloid content, and formulators should treat periwinkle leaf material as a pharmaceutical feedstock rather than an ingredient.

Commercial vinblastine is produced by extraction from periwinkle biomass, most efficiently via the monomeric precursors catharanthine and vindoline, which are chemically coupled to anhydrovinblastine and then reduced to vinblastine. Because the intact dimer is present at only trace levels in the plant, this precursor-and-coupling route dominates manufacturing, and analytical control relies on HPLC against reference standards with strict impurity limits.

For the formulator the boundary is the same as for vincristine: vinblastine sits firmly inside regulated pharmaceutical supply, not the standardised-botanical catalogue. This monograph documents the compound so its place in the vinca family — and its relationship to catharanthine, vindoline, and vincristine elsewhere in HerbIQ — is clear, without implying any sourcing route.

---

Frequently Asked Questions — Vinblastine

What is vinblastine?
Vinblastine (vincaleukoblastine) is a dimeric indole vinca alkaloid from Catharanthus roseus and was the first of the periwinkle vinca alkaloids to be isolated and characterised. It is used pharmaceutically as an antimitotic chemotherapy agent, most prominently in Hodgkin lymphoma and testicular-cancer regimens, and is not a dietary supplement.

How does vinblastine differ from vincristine?
Both share the catharanthine-vindoline vinca scaffold and the same tubulin-binding mechanism, differing by only one N-substituent. Clinically the divergence is significant: vinblastine's dose-limiting toxicity is myelosuppression (bone-marrow suppression), whereas vincristine's is peripheral neuropathy. This lets the two be used in different regimens according to which toxicity is more tolerable.

Is vinblastine a supplement ingredient?
No. It is a prescription cytotoxic drug administered intravenously by oncologists, with no dietary-supplement or food use. HerbIQ lists it as a chemical-family reference within the vinca alkaloids, not as a sourceable ingredient.

How is vinblastine produced commercially?
Vinblastine is obtained by extraction from Catharanthus roseus biomass, most efficiently via its monomeric precursors catharanthine and vindoline, which are coupled chemically to anhydrovinblastine and then reduced. This route is used because the intact dimer occurs at extremely low abundance in the plant, and it has motivated extensive work on engineered microbial biosynthesis of the precursors.

Related compounds: Vincristine, Catharanthine, Vindoline, Reserpine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery